Evidence map›Paper›PMID 41166403›Full record

ArticlePloS one2025

Antibiotic consumption in 14 countries of sub-Saharan Africa: Findings from a retrospective analysis.

Yvon de Jong, Rachit Singhal, Yewande Alimi, Geetanjali Kapoor, Abdourahmane Sow, Martin Matu, Edwin Shumba, Manuel Moreira, Deepak Batra, Ramanan Laxminarayan and 2 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Climate change and antimicrobial resistance.Nature reviews. Microbiology · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yvon de JongIQVIA, Centurion, South Africa and Dubai, UAE.
Rachit SinghalIQVIA, Centurion, South Africa and Dubai, UAE.
Yewande AlimiAfrica Centers for Disease Control and Prevention (Africa CDC), Surveillance and Disease Intelligence Division, African Union, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0002-2984-7817
Geetanjali KapoorOne Health Trust, Washington, DC, WA, United States of America.
Abdourahmane SowWest Africa Health Organization, Bobo Dioulasso, Burkina Faso.
Martin MatuEastern, Central and Southern African Health Community, Lusaka, Zambia.
Edwin ShumbaAfrican Society for laboratory Medicine, Addis Ababa, Ethiopia.
Manuel MoreiraInnovative Support to Emergencies, Diseases and Disasters (InSTEDD), Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-4563-5873
Deepak BatraIQVIA, Centurion, South Africa and Dubai, UAE.
Ramanan LaxminarayanOne Health Trust, Washington, DC, WA, United States of America.
Pascale OndoaAfrican Society for laboratory Medicine, Addis Ababa, Ethiopia.ORCID https://orcid.org/0000-0002-2700-9000
MAAP study group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntimicrobial consumption (AMC) measures the level and types of antibiotics consumed in a specific setting. Monitoring AMC is critical component of antimicrobial resistance (AMR) containment strategies. However, AMC data at both facility and national-levels are scarce in Africa, which limits our understanding of the rate, patterns and drivers of antibiotic consumption, and prevents the establishment of evidence-based antimicrobial stewardship.

methodsWe determined facility and national-level rates and patterns of AMC from data retrospectively collected between 2016 and 2019 in 327 pharmacies from 14 countries AMC data collection followed a backfilling strategy leveraging from public and private central medical stores, wholesalers, distributors or import services as data sources. Participating hospital and community pharmacies were selected based on their location in or proximity to hospitals capable of producing AMR data. Levels of AMC were determined as defined daily dose (DDD) and DDD per inhabitant (DID). AMC patterns were analysed according to the WHO Access, Watch, and Reserve (AWaRe) Categories, the Anatomical Therapeutic Chemical (ATC) classes and the individual antibiotic molecules included in the Drug Utilisation 75% (DU75). The availability of antibiotics was examined against the WHO and the National Essential Medicine Lists (EML).

resultsNational AMC data was available in 11 of the 14 participating countries, revealing a collective AMC of 8.42 DID varying from 2.8 to 115.5 at individual country level. AMC was also determined in 327 hospital and community pharmacies. Nine of 11 (82%) countries with national data available, and 219 of the 327 (72%) participating pharmacies achieved the WHO AWaRe target of at least 60% of antibiotic consumption from Access drugs. Eighty percent of country-level AMC was accounted for by five ATC sub-classes classes of antibacterial for systemic use. Facility-level antibiotic consumption was dominated by a narrow scope of less than five drugs, taking advantage of only 10% of all possible WHO-recommended Access drugs within ATC classes. Collectively, the 14 national EML included 70% of Access, 60% of Watch and less than 5% of Reserve antibiotics listed in the WHO EML. Forty-eight uncategorized and 50 categorized non-WHO-recommended drugs were included in national EMLs or documented to be circulating in countries.

interpretationThe relatively low AMC and the poorly diversified subset of antibiotics available in countries underscores that strategies to expand equitable access to adequate treatment of bacterial infections should complement current efforts to promote the judicious use of antimicrobials. Interventions to increase the volume of analysable data on AMU, AMC and AMR, should be prioritized in national AMR action plans as well as in wider infrastructural and economic development plans.

Indexed as

Anti-Bacterial AgentsDrug UtilizationAfrica South of the SaharaAntimicrobial StewardshipHumansRetrospective StudiesAnti-Bacterial Agents

Identifiers

PMID41166403
PMCPMC12574848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.